{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:22:16Z","timestamp":1780633336855,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jval.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:01:42Z","timestamp":1630458102000},"page":"1746-1753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data"],"prefix":"10.1016","volume":"24","author":[{"given":"Woojung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu My","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2021.07.004_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2021.07.004_bib2","author":"Becker"},{"key":"10.1016\/j.jval.2021.07.004_bib3","author":"Li"},{"issue":"7","key":"10.1016\/j.jval.2021.07.004_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jval.2020.12.018","article-title":"Broadening the concept of value: a scoping review on the option value of medical technologies","volume":"24","author":"Fornaro","year":"2021","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2021.07.004_bib5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hec.3899","article-title":"Do cancer treatments have option value? Real-world evidence from metastatic melanoma","volume":"28","author":"Li","year":"2019","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2021.07.004_bib6","author":"Chapman"},{"issue":"11 Suppl","key":"10.1016\/j.jval.2021.07.004_bib7","first-page":"S265","article-title":"The option value of innovative treatments in the context of chronic myeloid leukemia","volume":"18","author":"Sanchez","year":"2012","journal-title":"Am J Manag Care"},{"issue":"10","key":"10.1016\/j.jval.2021.07.004_bib8","first-page":"e340","article-title":"The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma","volume":"23","author":"Snider","year":"2017","journal-title":"Am J Manag Care"},{"issue":"7","key":"10.1016\/j.jval.2021.07.004_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jval.2019.02.002","article-title":"How does option value affect the potential cost-effectiveness of a treatment? The case of ipilimumab for metastatic melanoma","volume":"22","author":"Li","year":"2019","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2021.07.004_bib10","article-title":"The option value of innovation","volume":"15","author":"Snider","year":"2012","journal-title":"Forum Health Econ Policy"},{"key":"10.1016\/j.jval.2021.07.004_bib11","author":"Philipson"},{"issue":"1","key":"10.1016\/j.jval.2021.07.004_bib12","article-title":"The option value of innovative treatments for metastatic melanoma","volume":"21","author":"Snider","year":"2018","journal-title":"Forum Health Econ Policy"},{"issue":"26","key":"10.1016\/j.jval.2021.07.004_bib13","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for\u00a0previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2021.07.004_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejca.2009.10.032","article-title":"Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline","volume":"46","author":"Garbe","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2021.07.004_bib15","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Melanoma, Version2; 2011. https:\/\/ella.sheba.co.il\/webfiles\/shebaPics\/shebaella\/files\/47_mb_file_298f9.pdf. Accessed August 12, 2021."},{"key":"10.1016\/j.jval.2021.07.004_bib16","author":"Ma"},{"key":"10.1016\/j.jval.2021.07.004_bib17","author":"Birnbaum"},{"issue":"7","key":"10.1016\/j.jval.2021.07.004_bib18","first-page":"1","article-title":"United States life tables, 2017","volume":"68","author":"Arias","year":"2019","journal-title":"Natl Vital Stat Rep"},{"issue":"2","key":"10.1016\/j.jval.2021.07.004_bib19","first-page":"184","article-title":"Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumna\u00efveive patients with advanced melanoma in the United States","volume":"23","author":"Wang","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"26","key":"10.1016\/j.jval.2021.07.004_bib20","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521016430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521016430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:24:50Z","timestamp":1761096290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521016430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1098301521016430"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.07.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}